Antibody-dependent cellular cytotoxicity (ADCC) is a vital immune defense mechanism in which immune effector cells, primarily natural killer (NK) cells, recognize and destroy antibody-coated target cells. ADCC is essential in the mechanism of action of many therapeutic monoclonal antibodies, such as Rituximab and Trastuzumab, contributing significantly to their clinical efficacy. This immuno-cell killing assay serves as a critical functional assay in biologics development, regulatory evaluation, and biosimilar comparability studies.
BIOENSIS' ADCC assays enable the comprehensive evaluation of therapeutic antibody efficacy. As part of our cutting-edge immuno-oncology platform, this cell-based assay incorporates a diverse range of human primary immune cell types to deliver robust, predictive data on antibody function. By accurately modeling key physiological factors, such as cell-cell interactions, metabolic gradients, and antibody diffusion, our platform provides highly relevant insights into ADCC mechanisms. This immuno-cell killing assay supports the accelerated development of next-generation immunotherapies with improved translational potential.
Key assay features:
• Access to over 150 well-characterized tumor cell lines
• Primary cells available, including PBMCs, NK cells, and T cells
• High-throughput screening format for efficient and scalable testing
• Precision EC₅₀ determination for accurate potency assessment
• Flexible protocols accommodating both single agents and combination therapies
• Available in 2D and 3D cultures formats
Let us help you optimize your therapeutic strategy. Contact us today to discuss your study needs and request the most up-to-date list of available tumor cell lines.
info@bioensis.com
